BMT CTN Protocol  0202 -- Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem Cell  Transplantation (HSCT) for Patients with Chemosensitive Follicular Non-Hodgkin’s  Lymphoma Beyond First Complete Response or First Partial Response

Below are  protocol-related doucments, which may be periodically updated.

• Protocol synopsis,  version 4.0 dated January 17, 2006
• Protocol,  version 4.0 dated January 17, 2006
• Protocol amendment (highlights changes from version 3.0 to 4.0)
• Informed consents  (recipient and donor), version 4.0 dated January 17, 2006
• Health Quality of  Life (HQL)
• FACT in  English, version 4.0
• FACT in  Spanish, version 4.0
• SF-36 Health Status  Survey in English, version 2.0
• SF-36 Health Status  Survey in Spanish, version 2.0
• Participating  Centers
• Educational  Materials

• Key Personnel

  Protocol Co-Chair: Ginna Laport, MD (650-723-0822) glaport@stanford.edu

  Protocol Co-Chair: Robert Negrin, MD (650-727-1272) negrs@stanford.edu

  Protocol Officer:  Marcie Tomblyn, MD (612-624-5109) tombl001@umn.edu

  Protocol Coordinator: Christina Mandzuk (301-251-1161) cmandzuk@emmes.com

  Medical Monitor: Mary Eapen, MD (414-805-0700) meapen@mcw.edu

This protocol closed to patient accrual on March 2, 2006.